Table 1.
Description of Patient Demographic Characteristics at the Index Date When SU or TZD Was Added to Prior Metformin Therapy
| Characteristic |
All Patients N = 414 |
SU* + MF† n = 341 |
TZD** + MF† n = 73 |
| Age (mean yrs ± std) | 60.5 ± 9.5 | 61.0 ± 8.9 | 57.9 ± 11.3 |
| Female (%) | 49.8% | 49.0% | 53.4% |
| Current Smokers (%) | 13.5% | 13.5% | 13.7% |
| Zero alcohol consumption (%) | 42.5% | 43.1% | 39.7% |
| Absence of Regular Physical Activity (%) | 28.0% | 28.7% | 24.7% |
| Physical Activity 3–5 Times/Week (%) | 11.6% | 12.0% | 9.6% |
| Height (mean cm ± std) | 168.0 ± 8.7 | 168.0 ± 8.6 | 168.6 ± 9.3 |
| Weight (mean kg ± std) | 88.7 ± 15.5 | 88.5 ± 15.5 | 90.0 ± 15.4 |
| BMI (mean ± std) | 31.2 ± 4.7 | 31.2 ± 4.7 | 31.5 ± 4.8 |
| H/O‡ Micro-vascular Complications (%) | 8.0% | 8.5% | 5.5% |
| H/O‡ Macro-vascular Complications (%) | 26.5% | 25.8% | 27.4% |
| Years since T2DM Diagnosis (mean yrs ± std) | 6.6 ± 4.4 | 6.7 ± 4.4 | 6.2 ± 4.3 |
| A1C Level (mean A1C ± std) | 8.2 ± 1.5 | 8.3 ± 1.5 | 7.8 ± 1.2 |
* SU: Sulfonylurea
† MF: Metformin
** TZD: Thiazolidinedione
‡H/O: history of